CDKN1A upregulation and cisplatin-pemetrexed resistance in non-small cell lung cancer cells

Cisplatin-pemetrexed is a frequently adopted first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) ineligible for biological therapy, notwithstanding its limited efficacy. In the present study, the RAL cell line, an epidermal growth factor receptor (EGFR)-wild-type, p53-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zamagni, Alice, Pasini, Alice, Pirini, Francesca, Ravaioli, Sara, Giordano, Emanuele, Tesei, Anna, Calistri, Daniele, Ulivi, Paola, Fabbri, Francesco, Foca, Flavia, Delmonte, Angelo, Molinari, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170038/
https://www.ncbi.nlm.nih.gov/pubmed/32236605
http://dx.doi.org/10.3892/ijo.2020.5024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170038/
https://www.ncbi.nlm.nih.gov/pubmed/32236605
http://dx.doi.org/10.3892/ijo.2020.5024

Ejemplares similares